SCHEDULE: Ayrton Capital Discloses 9.99% Stake in GeoVax Labs

Ayrton Capital LLC, along with Alto Opportunity Master Fund and Waqas Khatri, reported a 9.99% beneficial ownership stake in GeoVax Labs, primarily through warrants.

Summary

• Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri collectively reported beneficial ownership of 4,810,451 shares of GeoVax Labs, Inc. common stock.
• This represents 9.99% of the company's outstanding common stock.
• The ownership primarily consists of shares issuable upon the exercise of certain warrants held by the reporting persons.
• The calculation of the percentage is based on 43,303,682 shares outstanding as of December 22, 2025, plus the 4,810,451 shares issuable from warrants.
• The warrants are subject to beneficial ownership blockers of 4.99% and 9.99%.
• Ayrton Capital LLC serves as the investment manager for Alto Opportunity Master Fund, and Waqas Khatri is the managing member of Ayrton Capital LLC and a director of the Fund.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional stake, particularly through warrants, can signal investor confidence and potential future capital infusion for GeoVax Labs.

Positives

• A significant institutional investor, Ayrton Capital LLC, and its affiliates have taken a substantial stake, potentially signaling confidence in GeoVax Labs' future.
• The ownership is primarily through warrants, which, upon exercise, would inject capital into GeoVax Labs.

Negatives

• The 9.99% ownership blocker suggests a strategic limit to avoid triggering certain regulatory or corporate governance thresholds, which could limit immediate activist potential.

Risks

• The beneficial ownership is largely derived from warrants, meaning the actual common stock shares are not yet fully owned and depend on future exercise decisions.
• The existence of beneficial ownership blockers (4.99% and 9.99%) could limit the reporting persons' ability to exert greater influence or control over the issuer, even with a significant stake.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, often indicating a long-term investment thesis by sophisticated investors. For a biotechnology company like GeoVax Labs, attracting such investment can be a positive signal, especially if the warrants are exercised, providing capital for R&D or operations.

Comparison to Industry Standards

• A 9.99% stake is a substantial position for an institutional investor in a small-cap biotechnology company like GeoVax Labs, often signaling a belief in the company's long-term potential or specific pipeline assets.
• Compared to typical passive institutional investments, a stake near the 10% threshold, especially when derived from warrants, suggests a more strategic or opportunistic investment rather than just broad market exposure.
• For example, similar warrant-based investments have been seen in other emerging biotech firms where investors aim to participate in future upside while potentially providing capital through warrant exercise, such as the financing rounds observed in companies like Vaxart or Novavax during their development phases.

Stakeholder Impact

• Shareholders: Increased institutional ownership could be seen as a positive signal, potentially attracting more investors and stabilizing the stock. The exercise of warrants could lead to dilution but also provide capital.
• Company Management: The presence of a significant shareholder group may lead to increased scrutiny or engagement regarding strategic decisions and operational performance.

Key Dates

Recommendation

The disclosure of a significant 9.99% beneficial ownership stake by Ayrton Capital and its affiliates, primarily through warrants, suggests a strategic investment. While the potential for future capital infusion upon warrant exercise is positive, the current filing is a disclosure of ownership rather than a performance update. Investors should hold to observe the impact of this significant stake and any subsequent actions by the reporting persons or GeoVax Labs, such as warrant exercises or strategic collaborations.

Keywords

GeoVax Labs, Ayrton Capital, Alto Opportunity Master Fund, Waqas Khatri, Schedule 13G, Beneficial Ownership, Warrants, Common Stock, Institutional Investor, SEC Filing